Evidence map›Paper›PMID 31841561›Full record

ArticlePLoS pathogens2019

Novel replisome-associated proteins at cellular replication forks in EBV-transformed B lymphocytes.

Huanzhou Xu, Ramon D Perez, Tiffany R Frey, Eric M Burton, Sudha Mannemuddhu, John D Haley, Michael T McIntosh, Sumita Bhaduri-McIntosh

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. [Functional investigation of chimeric antigen receptor T cells targeting LMP1 antigen].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Huanzhou XuDivision of Infectious Disease, Department of Pediatrics, University of Florida, Gainesville, Florida, United States of America.
Ramon D PerezDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New Yordk, Unites States of America.
Tiffany R FreyDivision of Infectious Disease, Department of Pediatrics, University of Florida, Gainesville, Florida, United States of America.ORCID 0000-0002-4247-6715
Eric M BurtonDivision of Infectious Disease, Department of Pediatrics, University of Florida, Gainesville, Florida, United States of America.
Sudha MannemuddhuDivision of Nephrology, Dept. of Pediatrics, University of Florida, Gainesville, Florida, United States of America.
John D HaleyDepartment of Pathology and Stony Brook Proteomics Center, Stony Brook University, Stony Brook, New York, United States of America.
Michael T McIntoshChild Health Research Institute, Department of Pediatrics and of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, United States of America.
Sumita Bhaduri-McIntoshDivision of Infectious Disease, Departments of Pediatrics and of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, United States of America.ORCID 0000-0003-2946-9497
University of Florida · USStony Brook University · USUniversity of Florida Health Science Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Host determinants of Epstein-Barr virus lytic cycle activationR01AI113134 · NIAID · UNIVERSITY OF FLORIDA · PI BHADURI-MCINTOSH, SUMITA · 2014 to 2018
$1.9M
NCATS NIH HHS UL1 TR001863NIAID NIH HHS R01 AI113134
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) is an oncogenic herpesvirus and WHO class 1 carcinogen that resides in B lymphocytes of nearly all humans. While silent in most, EBV can cause endemic Burkitt lymphoma in children and post-transplant lymphoproliferative disorders/lymphomas in immunocompromised hosts. The pathogenesis of such lymphomas is multifactorial but to a large extent depends on EBV's ability to aggressively drive cellular DNA replication and B cell proliferation despite cell-intrinsic barriers to replication. One such barrier is oncogenic replication stress which hinders the progression of DNA replication forks. To understand how EBV successfully overcomes replication stress, we examined cellular replication forks in EBV-transformed B cells using iPOND (isolation of Proteins on Nascent DNA)-mass spectrometry and identified several cellular proteins that had not previously been linked to DNA replication. Of eight candidate replisome-associated proteins that we validated at forks in EBV-transformed cells and Burkitt lymphoma-derived cells, three zinc finger proteins (ZFPs) were upregulated early in B cells newly-infected with EBV in culture as well as expressed at high levels in EBV-infected B blasts in the blood of immunocompromised transplant recipients. Expressed highly in S- and G2-phase cells, knockdown of each ZFP resulted in stalling of proliferating cells in the S-phase, cleavage of caspase 3, and cell death. These proteins, newly-identified at replication forks of EBV-transformed and Burkitt lymphoma cells therefore contribute to cell survival and cell cycle progression, and represent novel targets for intervention of EBV-lymphomas while simultaneously offering a window into how the replication machinery may be similarly modified in other cancers.

Indexed as

B-LymphocytesBurkitt LymphomaCell ProliferationCell Transformation, ViralEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHumansReplication OriginZinc Fingers

Identifiers

PMID31841561
PMCPMC6936862
OpenAlexW2994889674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.